Congleton Jon 4

What Happened
Jon Congleton, a director of Avalyn Pharma, was granted a derivative award covering 26,978 shares on April 29, 2026. The filing reports the acquisition at a $0.00 price (an award/grant of derivative securities), so there was no cash purchase or sale and no immediate proceeds.

Key Details

• Transaction date: 2026-04-29; Form 4 filed 2026-05-01 (timely filing).
• Transaction type/code: A — Grant/award of derivative securities.
• Shares/units involved: 26,978 (acquired as a derivative security). Reported acquisition price: $0.00.
• Shares owned after transaction: Not specified in the provided filing details.
• Footnote (vesting): 25% of the shares underlying this option vested on September 12, 2025; the remaining 75% vest in thirty-six equal monthly installments thereafter, subject to continued service.

Context
This was a grant of a derivative award (typically an option or similar instrument) rather than a cash purchase or sale. The award vests over time per the schedule above; it was not reported as an immediate exercise or sale, so it does not reflect an immediate buy or sell in the open market.